ipilimumab,nivolumab
bms
['melanoma']
excellent results with neoadjuvant immunotherapy without tlnd or adjuvant therapy in pts with stage iiib/c melanoma demonstrated in the prado study (2-year rfs and dmfs 93% and 98%, respectively), as now reported at #asco22 and published in nature medicine. 
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.